93 related articles for article (PubMed ID: 24638068)
1. The invariant chain p35 isoform promotes formation of nonameric complexes with MHC II molecules.
Cloutier M; Gauthier C; Fortin JS; Thibodeau J
Immunol Cell Biol; 2014 Jul; 92(6):553-6. PubMed ID: 24638068
[TBL] [Abstract][Full Text] [Related]
2. ER egress of invariant chain isoform p35 requires direct binding to MHCII molecules and is inhibited by the NleA virulence factor of enterohaemorrhagic Escherichia coli.
Cloutier M; Gauthier C; Fortin JS; Genève L; Kim K; Gruenheid S; Kim J; Thibodeau J
Hum Immunol; 2015 Apr; 76(4):292-6. PubMed ID: 25731712
[TBL] [Abstract][Full Text] [Related]
3. Invariant chain-MHC class II complexes: always odd and never invariant.
Cresswell P; Roche PA
Immunol Cell Biol; 2014 Jul; 92(6):471-2. PubMed ID: 24777311
[No Abstract] [Full Text] [Related]
4. The MHC class II beta chain cytoplasmic tail overcomes the invariant chain p35-encoded endoplasmic reticulum retention signal.
Khalil H; Brunet A; Saba I; Terra R; Sékaly RP; Thibodeau J
Int Immunol; 2003 Oct; 15(10):1249-63. PubMed ID: 13679394
[TBL] [Abstract][Full Text] [Related]
5. Transport properties of free and MHC class II-associated oligomers containing different isoforms of human invariant chain.
Arunachalam B; Lamb CA; Cresswell P
Int Immunol; 1994 Mar; 6(3):439-51. PubMed ID: 8186195
[TBL] [Abstract][Full Text] [Related]
6. A three-amino-acid-long HLA-DRbeta cytoplasmic tail is sufficient to overcome ER retention of invariant-chain p35.
Khalil H; Brunet A; Thibodeau J
J Cell Sci; 2005 Oct; 118(Pt 20):4679-87. PubMed ID: 16188937
[TBL] [Abstract][Full Text] [Related]
7. NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ.
Karosiene E; Rasmussen M; Blicher T; Lund O; Buus S; Nielsen M
Immunogenetics; 2013 Oct; 65(10):711-24. PubMed ID: 23900783
[TBL] [Abstract][Full Text] [Related]
8. The transmembrane domain and luminal C-terminal region independently support invariant chain trimerization and assembly with MHCII into nonamers.
Cloutier M; Fortin JS; Thibodeau J
BMC Immunol; 2021 Aug; 22(1):56. PubMed ID: 34384367
[TBL] [Abstract][Full Text] [Related]
9. The human-specific invariant chain isoform Iip35 modulates Iip33 trafficking and function.
Sand KM; Landsverk OJ; Berg-Larsen A; Bakke O; Gregers TF
Immunol Cell Biol; 2014 Oct; 92(9):791-8. PubMed ID: 24983457
[TBL] [Abstract][Full Text] [Related]
10. Human invariant chain isoform p35 restores thymic selection and antigen presentation in CD74-deficient mice.
Genève L; Chemali M; Desjardins M; Labrecque N; Thibodeau J
Immunol Cell Biol; 2012 Oct; 90(9):896-902. PubMed ID: 22689013
[TBL] [Abstract][Full Text] [Related]
11. Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes.
Lamb CA; Cresswell P
J Immunol; 1992 Jun; 148(11):3478-82. PubMed ID: 1588042
[TBL] [Abstract][Full Text] [Related]
12. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
13. Type 1 diabetes associated HLA-DQ2 and DQ8 molecules are relatively resistant to HLA-DM mediated release of invariant chain-derived CLIP peptides.
Zhou Z; Reyes-Vargas E; Escobar H; Rudd B; Rockwood AL; Delgado JC; He X; Jensen PE
Eur J Immunol; 2016 Apr; 46(4):834-45. PubMed ID: 26707565
[TBL] [Abstract][Full Text] [Related]
14. HLA-DQA2 and HLA-DQB2 genes are specifically expressed in human Langerhans cells and encode a new HLA class II molecule.
Lenormand C; Bausinger H; Gross F; Signorino-Gelo F; Koch S; Peressin M; Fricker D; Cazenave JP; Bieber T; Hanau D; de la Salle H; Tourne S
J Immunol; 2012 Apr; 188(8):3903-11. PubMed ID: 22407913
[TBL] [Abstract][Full Text] [Related]
15. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.
Teyton L; O'Sullivan D; Dickson PW; Lotteau V; Sette A; Fink P; Peterson PA
Nature; 1990 Nov; 348(6296):39-44. PubMed ID: 2234057
[TBL] [Abstract][Full Text] [Related]
16. Molecular requirements for the interaction of class II major histocompatibility complex molecules and invariant chain with calnexin.
Arunachalam B; Cresswell P
J Biol Chem; 1995 Feb; 270(6):2784-90. PubMed ID: 7852350
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of MHCII genes by PRMT6, via an AT-hook motif of RFX5.
Stavride P; Arampatzi P; Papamatheakis J
Mol Immunol; 2013 Dec; 56(4):390-8. PubMed ID: 23911394
[TBL] [Abstract][Full Text] [Related]
18. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
Neumann J; König A; Koch N
Int Immunol; 2007 Jan; 19(1):31-9. PubMed ID: 17105964
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evidence for high frequency of I-Ab-reactive CD4+ T cells in HLA-DQ or HLA-DRA transgenic mice lacking endogenous MHC class I and/or class II expression.
Ishimoto T; Yamamoto K; Fukui Y; Fukuda Y; Dohi K; Sasazuki T
J Immunol; 1997 Oct; 159(8):3717-22. PubMed ID: 9378957
[TBL] [Abstract][Full Text] [Related]
20. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
